The framework has had a lukewarm reaction, with trade association EFPIA saying the policies are “not strong enough”.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

Zealand Pharma and OTR Therapeutics are to collaborate to discover and develop therapies for several targets in metabolic diseases.

Novartis and Relation's target discovery deal falls under Novartis’ wider ploy to strengthen its immunology portfolio.

Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...

The UK's 14.5% drug rebate reduction may help to quell souring pharma sentiments, which stem from the nation's low spending on innovative drugs.

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006 from Lynk Pharmaceuticals.

Golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as a monotherapy and ...

We explore the challenges and opportunities of eco-design in parenteral packaging, from alternative feedstocks and carbon ...

At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.